Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease

• Status: Completed
• Trial end date: 2014-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the safety and efficacy of two different doses of Pasireotide in patients with de novo or recurrent/persistent Cushing's Disease.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Pasireotide; Somatostatin

Criteria

Inclusion criteria

• 18 years or greater

• Confirmed diagnosis of ACTH-dependent Cushing's disease

• Not considered candidate for pituitary surgery

Exclusion criteria

• History of pituitary irradiation in the last 10 years

• Cushing's syndrome not caused by pituitary tumor

• Patients with active malignant disease (cancer) in the last 5 years

• Women who are pregnant or lactating

Other protocol-defined inclusion/exclusion criteria apply.